Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease.
Laszlo A GrohLoes H WillemsPaula FintelmanMichel M P J ReijnenSaloua El MessaoudiMichiel C WarléPublished in: Cardiology and therapy (2023)
ClinicalTrials.gov ID: NCT05210725.